AXS-12, known as reboxetine back when it was available as an antidepressant in the United States, may decrease cataplexy ...

The study reviewed US medical claims databases from 2005 to 2021 and compared CVD outcomes in narcolepsy patients and ...

The link between narcolepsy and cardiovascular disease (CVD) was strengthened by new evidence that the relationship applied ...

For the next in our series of conditions GPs might rarely encounter, Neurology consultant Dr Clare Bolton provides an ...

Some common narcolepsy comorbidities include obstructive sleep apnea (OSA), attention deficit hyperactivity disorder (ADHD), restless legs syndrome (RLS), anxiety, and depression. Comorbidities ...

In SYMPHONY, AXS-12 was well tolerated with no new safety signals, Thorpy said. The main adverse effects were gastrointestinal, including dry mouth, nausea, constipation, and decreased appetite. One ...

USA: A retrospective cohort study using Medicare and commercial insurance data has found that narcolepsy is associated with ...

Among patients with narcolepsy, AXS-12 (reboxetine) vs placebo significantly reduced the frequency of cataplexy attacks.

Ahead of a planned trial next month, Jazz Pharmaceuticals is moving to resolve antitrust allegations surrounding its key ...

Retrospective analysis reveals no significant differences in comorbidities in narcolepsy patients treated vs. not treated with sodium oxybate ...